KYRNF (Kyorin Pharmaceutical Co) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYRNF Kyorin Pharmaceutical Co Ltd KYRNF
69 GF Score
Price $10.31
GF Value $14.91
! 7 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyorin Pharmaceutical Co  (OTCPK:KYRNF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 1.17 1.15 0.63 0.62

Kyorin Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.62 0.62 0.61 0.61

KYRNF vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


KYRNF
69GF Score
Kyorin Pharmaceutical Co Ltd KYRNF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kyorin Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.239/113.6000*113.6000
=3.239

Current CPI (Jun. 2026) = 113.6000.

Kyorin Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.582 98.000 4.152
201612 4.007 98.400 4.626
201703 3.419 98.100 3.959
201706 3.237 98.500 3.733
201709 2.973 98.800 3.418
201712 3.868 99.400 4.421
201803 3.471 99.200 3.975
201806 3.121 99.200 3.574
201809 3.065 99.900 3.485
201812 4.340 99.700 4.945
201903 5.008 99.700 5.706
201906 4.088 99.800 4.653
201909 3.667 100.100 4.162
201912 4.868 100.500 5.503
202003 5.025 100.300 5.691
202006 4.008 99.900 4.558
202009 3.788 99.900 4.307
202012 4.546 99.300 5.201
202103 4.597 99.900 5.227
202106 3.938 99.500 4.496
202109 3.869 100.100 4.391
202112 4.391 100.100 4.983
202203 4.174 101.100 4.690
202206 3.315 101.800 3.699
202209 3.088 103.100 3.402
202212 3.900 104.100 4.256
202303 4.292 104.400 4.670
202306 3.538 105.200 3.821
202309 3.261 106.200 3.488
202312 3.805 106.800 4.047
202403 3.783 107.200 4.009
202406 3.176 108.200 3.335
202409 3.117 108.900 3.252
202412 3.901 110.700 4.003
202503 4.660 111.100 4.765
202506 3.640 111.700 3.702
202509 3.365 112.000 3.413
202512 3.810 113.000 3.830
202603 3.750 112.700 3.780
202606 3.239 113.600 3.239

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of $10.31 is trading 30.9% below its estimated GF Value™ of $14.91.

Key valuation signals for KYRNF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $14.91 vs. price of $10.31 (30.9% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyorin Pharmaceutical Co Business Description

Other Exchanges 4569:Japan
Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
69GF Score

Get the complete analysis for KYRNF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.31
Price
$14.91
GF Value